Skin regeneration with conical and hair follicle structure of deep second-degree scalding injuries via combined expression of the EPO receptor and beta common receptor by local subcutaneous injection of nanosized rhEPO

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 1227-1237

  Bader, Augustinus ^a   Ebert, Sabine ^a   Giri, Shibashish ^a   Kremer, Mathias ^b   Liu, Shuhua ^b   Nerlich, Andreas ^e   Günter, Christina I ^c   Smith, Dagmar U ^d   Machens, Hans Günther ^b,c  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e Chirurgische Klinik Munchen Bogenhausen   (Germany)

Author keywords

Burns; Common subunit; Erythropoietin; Local injection; Nanosize; Receptor

Indexed keywords

COMMON BETA SUBUNIT RECEPTOR; ERYTHROPOIETIN RECEPTOR; GROWTH HORMONE RECEPTOR; MESSENGER RNA; RECEPTOR; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; ERYTHROPOIETIN; NANOPARTICLE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONICAL STRUCTURE; CONTROLLED STUDY; DERMIS; DISEASE SEVERITY; DRUG EFFICACY; EPIDERMIS; EPITHELIZATION; FEMALE; GENE EXPRESSION; HAIR FOLLICLE; HISTOPATHOLOGY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCALD; SKIN PROTECTION; SKIN REGENERATION; TISSUE REGENERATION; TISSUE STRUCTURE; TREATMENT DURATION; WESTERN BLOTTING; WOUND CLOSURE; WOUND HEALING; ANIMAL; BAGG ALBINO MOUSE; BURN; CYTOCHEMISTRY; DRUG EFFECT; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METABOLISM; PROTEIN SUBUNIT; SKIN; SUBCUTANEOUS DRUG ADMINISTRATION;

MUS;

ANIMALS; BURNS; EPIDERMIS; ERYTHROPOIETIN; FEMALE; GENE EXPRESSION PROFILING; HAIR FOLLICLE; HISTOCYTOCHEMISTRY; HUMANS; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED BALB C; NANOPARTICLES; PROTEIN SUBUNITS; RECEPTORS, ERYTHROPOIETIN; RECEPTORS, SOMATOTROPIN; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN; WOUND HEALING;

EID: 84862339406     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S28186     Document Type: Article

References (24)

1. Jeschke MG, Chinkes DL, Finnerty CC, et al. Pathophysiologic response to severe burn injury. Ann Surg. 2008;248:387-401.
2. Avni T, Levcovich A, Ad-El DD, Leibovici L, Paul M. Prophylactic antibiotics for burns patients: systematic review and meta-analysis. BMJ. 2010;340:c241.
3. Galeano M, Altavilla D, Cucinotta D, et al. Recombinant human erythropoietin stimulates angiogenesis and wound healing in the genetically diabetic mouse. Diabetes. 2004;53:2509-2517.
4. Sorg H, Krueger C, Schulz T, Menger MD, Schmitz F, Vollmar B. Effects of erythropoietin in skin wound healing are dose related. FASEB J. 2009;23:3049-3058.
5. Hamed S, Ullmann Y, Masoud M, Hellou E, Khamaysi Z, Teot L. Topical erythropoietin promotes wound repair in diabetic rats. J Invest Dermatol. 2010;130:287-294.
6. Bader A, Lorenz K, Richter A, et al. Interactive role of trauma cytokines and erythropoietin and their therapeutic potential for acute and chronic wounds. Rejuvenation Res. 2011;14:57-66.
7. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signalling through a variety of cytokine receptors. Cell. 1998;93:385-395.
8. Bodó E, Kromminga A, Funk W, et al. Human hair follicles are an extrarenal source and a nonhematopoietic target of erythropoietin. FASEB J. 2007;21:3346-3354.
9. Jelkmann W. Molecular biology of erythropoietin. Intern Med. 2004;8:649-659.
10. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A. 2004;101:14907-14912.
11. Brines M, Cerami A. Erythropoietin mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med. 2008;264:405-432.
12. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol. 2008;67:39-61.
13. Scott CL, Robb L, Papaevangeliou B, Mansfield R, Nicola NA, Begley CG. Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony stimulating factor, or stem cell factor. Blood. 2000;96:1588-1590.
14. LeBaron MJ, Ahonen TJ, Nevalainen MT, Rui H. In vivo responsebased identification of direct hormone target cell populations using high-density tissue arrays. Endocrinology. 2007;148:989-1008.
15. Galeano M, Altavilla D, Bitto A, et al. Recombinant human erythropoietin improves angiogenesis and wound healing in experimental burn wounds. Crit Care Med. 2006;34:1139-1146.
16. Saqib N, Dulin L, Krier K, Howdieshell TR. Temporal and spatial expression of erythropoietin, erythropoietin receptor, and common t receptor in wound fluid and granulation. Wounds. 2009;21:7.
17. Lorenz K, Sicker M, Schmelzer E, et al. Multilineage differentiation potential of human dermal skin-derived fibroblasts. Exp Dermatol. 2008;11:925-932.
18. Herndon DN, Hawkins HK, Nguyen TT, Pierre E, Cox R, Barrow RE. Characterization of growth hormone enhanced donor site healing in patients with large cutaneous burns. Ann Surg. 1995;221:649-656.
19. Elliott S, Busse L, Bass MB. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood. 2006;107:1892-1895.
20. Paus R, Bodó E, Kromminga A, Jelkmann W. Erythropoietin and the skin: a role for epidermal oxygen sensing? Bioessays. 2009;31: 344-348.
21. Cohan RA, Madadkar-Sobhani A, Khanahmad H, et al. Design, modeling, expression, and chemoselective PEGylation of a new nanosize cysteine analog of erythropoietin. Int J Nanomedicine. 2011;6: 1217-1227.
22. Cheetham JC, Smith DM, Aoki KH, et al. NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat Struct Biol. 1998;5:861-866.
23. Wang T, Hu Y, Leach MK, et al. Erythropoietin-loaded oligochitosan nanoparticles for treatment of periventricular leukomalacia. Int J Pharm. 2012;422:462-471.
24. Khachane P, Date AA, Nagarsenker MS. Eudragit EPO nanoparticles: application in improving therapeutic efficacy and reducing ulcerogenicity of meloxicam on oral administration. J Biomed Nanotechnol. 2011;7:590-597.